Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-(p-sulfophenyl)-theophylline is a synthetic, highly water-soluble derivative of theophylline, which belongs to the methylxanthine family.[1][2][3] It acts as a competitive antagonist at adenosine receptors, with notable selectivity for the A2A adenosine receptor subtype (Ki ≈ 57 nM) over A1 (Ki ≈ 3.2 μM), and is essentially inactive at A2B and A3 subtypes at typical concentrations.[1] Its competitive antagonism occurs at the orthosteric binding site, causing functional blockade of adenosine-induced signaling, particularly pathways mediated by Gs and Gi proteins (modulating cAMP and PKA activity).[1] The presence of the p-sulfophenyl group confers strong hydrophilicity and poor blood-brain barrier penetration, meaning it acts predominantly peripherally when administered in vivo. The drug is primarily used as a research tool for investigating peripheral adenosine signaling, cardiovascular pharmacology, and adenosine receptor biology, rather than as a marketed pharmaceutical. It may also modulate phospholipase C-related pathways in relevant tissue models.[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-(p-sulfophenyl)-theophylline.